PDCD1 and esophageal cancer: In recent years, immunotherapy with Programmed Cell Death Protein 1 (PD‐1)/Programmed Cell Death‐Ligand 1 (PD‐L1) drugs have shown promising results in significantly prolonging overall survival (OS) in esophageal cancer patients.5